stockrow
Saturday 7 November 2026
Export GPCR’s income statement to Excel — free account
Structure Therapeutics Inc. Sponsored ADR
GPCR Healthcare Biotechnology
- EPS
- −36.4%
- Free cash flow
- −119.2%
Quarter to June 2026, against a year earlier
20.33
1.25
+6.55%
Follow GPCR
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 42 | 0 | 153 | +91.4% | |
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | — | — | (16) | (38) | (51) | (89) | (122) | (141) | (214) | +54.9% | ||||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | (16) | (38) | (51) | (90) | (123) | (141) | (215) | +54.8% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | (0.44) | (16.13) | (16.06) | (2.44) | (2.33) | (2.39) | (3.11) | +40.2% | ||||||
| Cash flow | — | — | — | — | (0.39) | (11.85) | (14.44) | (2.16) | (2.22) | (3.75) | (3.03) | +57.2% | ||||||
| Capex | — | — | — | — | 0.00 | (0.44) | (0.05) | (0.06) | (0.02) | (0.06) | (0.06) | n/m | ||||||
| Free cash flow | — | — | — | — | (0.39) | (12.29) | (14.48) | (2.22) | (2.24) | (3.81) | (3.09) | +57.7% | ||||||
| Book value | — | — | — | — | 0.97 | 37.67 | 26.55 | 12.33 | 16.43 | 25.61 | 18.64 | +92.4% | ||||||
| Shares, m | — | — | — | — | 37 | 3 | 3 | 37 | 53 | 59 | 66 | +10.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (14) | (32) | (46) | (79) | (117) | (222) | (220) | +73.1% | |||||
| Capex | — | — | — | — | 0 | (1) | 0 | (2) | (1) | (4) | (4) | +185.7% | ||||||
| Free cash flow | — | — | — | — | (14) | (33) | (46) | (82) | (118) | (226) | (225) | +73.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 35 | 101 | 80 | 449 | 855 | 1,507 | 1,306 | +111.8% | |||||
| Net debt | — | — | — | — | (37) | (107) | (91) | (467) | (884) | (1,446) | (1,343) | +108.0% | ||||||
| Shareholders’ equity | — | — | — | — | 36 | 102 | 85 | 453 | 865 | 1,516 | 1,354 | +111.9% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (58.41) | (50.56) | (30.91) | (17.69) | (11.35) | (19.17) | (11.3) pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (157.24) | (1,371.78) | (157.2) pt | ||||||
| ROE | — | — | — | — | 0.00 | 100.37 | 58.75 | (53.06) | (18.60) | (11.86) | (20.21) | (11.9) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 68 | 68 | 93 | 163 | 220 | — | +34.1% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Structure Therapeutics Inc. Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AAPG Ascentage Pharma Group International - Unsponsored ADR | $1.4B | — | — | — | — | +17.74% (above 0%: growing) | — | — | Compare |
| OCUL Ocular Therapeutix, Inc. | $1.4B | — (loss-making) | — (loss-making) | +0.12% (above 0%: growing) | n/m | −25.35% (below 0%: shrinking) | 85.08% | (609.34%) | Compare |
| KRSA Korsana Biosciences, Inc. | $1.4B | — (loss-making) | — (loss-making) | −43.24% (below 0%: shrinking) | n/m | −184.69% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| GPCR Structure Therapeutics Inc. Sponsored ADR | $1.4B | — (loss-making) | — | — | n/m | −119.15% (below 0%: shrinking) | 0.00% | 0.00% | |
| ANAB AnaptysBio, Inc. | $1.4B | — (loss-making) | 220× | −7.98% (below 0%: shrinking) | n/m | −141.60% (below 0%: shrinking) | 100.00% | (135.53%) | Compare |
| DMRA Galecto, Inc. | $1.4B | 24.7× | — | — | n/m | −877.51% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MLYS Mineralys Therapeutics, Inc. | $1.4B | — (loss-making) | — | — | n/m | −7.91% (below 0%: shrinking) | — | 0.00% | Compare |
| TSHA Taysha Gene Therapies, Inc. | $1.3B | — (loss-making) | — (loss-making) | +206.77% (above 0%: growing) | n/m | −100.28% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| KARD KARDIGAN INC | $1.3B | — (loss-making) | — | — | n/m | — | — | 0.00% | Compare |
| Median of peers | $1.4B | — | — | −3.93% | — | −100.28% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 23 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 8.43m | 36.23m | 267.50 |
| 2024 | 5.74m | 1.74m | 104.31 |
| 2023 | 7.39m | 22.06m | 156.77 |
Ownership
Directors and executive officers, together
5.50%
Entities affiliated with FMR LLC
14.60%
Entities affiliated with Wellington Management Group LLP
10.00%
Entities affiliated with Avoro Capital Advisors LLC
9.60%
Entities affiliated with Janus Henderson Group plc
6.30%
Entities affiliated with Deep Track Capital, LP
5.80%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement